Cargando…

Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?

Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: De Martino, Viviana, Rossi, Michela, Battafarano, Giulia, Pepe, Jessica, Minisola, Salvatore, Del Fattore, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619425/
https://www.ncbi.nlm.nih.gov/pubmed/34830463
http://dx.doi.org/10.3390/ijms222212586
_version_ 1784604988378447872
author De Martino, Viviana
Rossi, Michela
Battafarano, Giulia
Pepe, Jessica
Minisola, Salvatore
Del Fattore, Andrea
author_facet De Martino, Viviana
Rossi, Michela
Battafarano, Giulia
Pepe, Jessica
Minisola, Salvatore
Del Fattore, Andrea
author_sort De Martino, Viviana
collection PubMed
description Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutics. However, the drug resistance and the side effects associated with the chemotherapy require the identification of new therapeutic approaches. The understanding of the complex biological scenario of the osteosarcoma will open the way for the identification of new targets for its treatment. Recently, a great interest of scientific community is for extracellular vesicles (EVs), that are released in the tumor microenvironment and are important regulators of tumor proliferation and the metastatic process. At the same time, circulating extracellular vesicles can be exploited as diagnostic and prognostic biomarkers, and they can be loaded with drugs as a new therapeutic approach for osteosarcoma patients. Thus, the characterization of OS-related EVs could represent a way to convert these vesicles from antagonists for human health into therapeutic and/or diagnostic agents.
format Online
Article
Text
id pubmed-8619425
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86194252021-11-27 Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents? De Martino, Viviana Rossi, Michela Battafarano, Giulia Pepe, Jessica Minisola, Salvatore Del Fattore, Andrea Int J Mol Sci Review Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutics. However, the drug resistance and the side effects associated with the chemotherapy require the identification of new therapeutic approaches. The understanding of the complex biological scenario of the osteosarcoma will open the way for the identification of new targets for its treatment. Recently, a great interest of scientific community is for extracellular vesicles (EVs), that are released in the tumor microenvironment and are important regulators of tumor proliferation and the metastatic process. At the same time, circulating extracellular vesicles can be exploited as diagnostic and prognostic biomarkers, and they can be loaded with drugs as a new therapeutic approach for osteosarcoma patients. Thus, the characterization of OS-related EVs could represent a way to convert these vesicles from antagonists for human health into therapeutic and/or diagnostic agents. MDPI 2021-11-22 /pmc/articles/PMC8619425/ /pubmed/34830463 http://dx.doi.org/10.3390/ijms222212586 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Martino, Viviana
Rossi, Michela
Battafarano, Giulia
Pepe, Jessica
Minisola, Salvatore
Del Fattore, Andrea
Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_full Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_fullStr Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_full_unstemmed Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_short Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_sort extracellular vesicles in osteosarcoma: antagonists or therapeutic agents?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619425/
https://www.ncbi.nlm.nih.gov/pubmed/34830463
http://dx.doi.org/10.3390/ijms222212586
work_keys_str_mv AT demartinoviviana extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
AT rossimichela extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
AT battafaranogiulia extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
AT pepejessica extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
AT minisolasalvatore extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
AT delfattoreandrea extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents